Phylogenetic sequence variations in bacterial rRNA affect species-specific susceptibility to drugs targeting protein synthesis

Antimicrob Agents Chemother. 2011 Sep;55(9):4096-102. doi: 10.1128/AAC.01398-10. Epub 2011 Jul 5.

Abstract

Antibiotics targeting the bacterial ribosome typically bind to highly conserved rRNA regions with only minor phylogenetic sequence variations. It is unclear whether these sequence variations affect antibiotic susceptibility or resistance development. To address this question, we have investigated the drug binding pockets of aminoglycosides and macrolides/ketolides. The binding site of aminoglycosides is located within helix 44 of the 16S rRNA (A site); macrolides/ketolides bind to domain V of the 23S rRNA (peptidyltransferase center). We have used mutagenesis of rRNA sequences in Mycobacterium smegmatis ribosomes to reconstruct the different bacterial drug binding sites and to study the effects of rRNA sequence variations on drug activity. Our results provide a rationale for differences in species-specific drug susceptibility patterns and species-specific resistance phenotypes associated with mutational alterations in the drug binding pocket.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / chemistry
  • Aminoglycosides / pharmacology
  • Binding Sites
  • Erythromycin / chemistry
  • Erythromycin / pharmacology
  • Ketolides / chemistry
  • Ketolides / pharmacology
  • Macrolides / chemistry
  • Macrolides / pharmacology
  • Microbial Sensitivity Tests
  • Mycobacterium smegmatis / genetics
  • Phylogeny*
  • RNA, Ribosomal / classification
  • RNA, Ribosomal / genetics*
  • RNA, Ribosomal, 16S / genetics
  • RNA, Ribosomal, 23S / genetics

Substances

  • Aminoglycosides
  • Ketolides
  • Macrolides
  • RNA, Ribosomal
  • RNA, Ribosomal, 16S
  • RNA, Ribosomal, 23S
  • Erythromycin
  • telithromycin